Forte Biosciences Inc. Stock News

Forte Biosciences (FBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Gainers Sharps Compliance Corp. (NASDAQ: SMED) shares jumped 196.1% to close at $8.44 on Tuesday after the company it will be acquired by an affiliate of Aurora Capital Partners for $8.75 per share.

Gainers Canoo Inc. (NASDAQ: GOEV) shares jumped 79.9% to $4.2627 after Walmart signed a definitive agreement with the company to purchase 4,500 all-electric delivery vehicles, beginning with the Life

What to know about buying penny stocks on May 3rd The post Best Penny Stocks to Buy Today? 3 to Watch on May 3rd appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

BiomX: Undervalued With Multiple Upcoming Catalysts

Los Angeles, California--(Newsfile Corp. - September 6, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of

The stock price of Forte Biosciences, Inc. (NASDAQ: FBRX) fell by 82.3% yesterday. This is why it happened.

LOS ANGELES--(BUSINESS WIRE)---- $FBRX #FBRX--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Forte Biosciences, Inc.

Forte's (FBRX) mid-stage study on its lead candidate FB-401 to address the condition of atopic dermatitis fails to meet its primary goal and the company decides to discontinue the study further.

Forte Biosciences (NASDAQ: FBRX) is tanking today after the company announced the clinical trial of FB-401 for the treatment of atopic dermatitis failed to meet statistical significance. “We are ap

NEW YORK, Sept. 3, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Forte Biosciences, Inc. ("Forte" or the "Company") (NASDAQ: FBRX).

The company announced dismal results from a phase 2 study of its only pipeline candidate.

Shares of Forte Biosciences Inc. FBRX, -4.45% plummeted 81.2% on heavy volume toward a record low in premarket trading Friday, after the biopharmaceutical company said it will no longer advance its le

A biopharmaceutical company focused on the development of dermatology treatments saw a sharp drop after hours Thursday. What Happened: The clinical trial of Forte Biosciences (NASDAQ: FBRX) lead drug

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced the issuance of an equity inducement award a